A Simplified and Effective Approach for the Isolation of Small Pluripotent Stem Cells Derived from Human Peripheral Blood
-
Published:2023-03-05
Issue:3
Volume:11
Page:787
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Filidou Eirini1ORCID, Kandilogiannakis Leonidas1ORCID, Tarapatzi Gesthimani1ORCID, Spathakis Michail1ORCID, Su Colin2, Rai Alin34, Greening David W.3456ORCID, Arvanitidis Konstantinos1ORCID, Paspaliaris Vasilis2, Kolios George1ORCID
Affiliation:
1. Laboratory of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Dragana, 68100 Alexandroupolis, Greece 2. Tithon Biotech Inc., San Diego, CA 92127, USA 3. Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia 4. Baker Department of Cardiovascular Research Translation and Implementation, La Trobe University, Melbourne, VIC 3086, Australia 5. Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC 3052, Australia 6. Central Clinical School, Monash University, Melbourne, VIC 3004, Australia
Abstract
Pluripotent stem cells are key players in regenerative medicine. Embryonic pluripotent stem cells, despite their significant advantages, are associated with limitations such as their inadequate availability and the ethical dilemmas in their isolation and clinical use. The discovery of very small embryonic-like (VSEL) stem cells addressed the aforementioned limitations, but their isolation technique remains a challenge due to their small cell size and their efficiency in isolation. Here, we report a simplified and effective approach for the isolation of small pluripotent stem cells derived from human peripheral blood. Our approach results in a high yield of small blood stem cell (SBSC) population, which expresses pluripotent embryonic markers (e.g., Nanog, SSEA-3) and the Yamanaka factors. Further, a fraction of SBSCs also co-express hematopoietic markers (e.g., CD45 and CD90) and/or mesenchymal markers (e.g., CD29, CD105 and PTH1R), suggesting a mixed stem cell population. Finally, quantitative proteomic profiling reveals that SBSCs contain various stem cell markers (CD9, ITGA6, MAPK1, MTHFD1, STAT3, HSPB1, HSPA4), and Transcription reg complex factors (e.g., STAT5B, PDLIM1, ANXA2, ATF6, CAMK1). In conclusion, we present a novel, simplified and effective isolating process that yields an abundant population of small-sized cells with characteristics of pluripotency from human peripheral blood.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference200 articles.
1. Potential Clinical Applications of Stem Cells in Regenerative Medicine;Suman;Adv. Exp. Med. Biol.,2019 2. Jarrige, M., Frank, E., Herardot, E., Martineau, S., Darle, A., Benabides, M., Domingues, S., Chose, O., Habeler, W., and Lorant, J. (2021). The Future of Regenerative Medicine: Cell Therapy Using Pluripotent Stem Cells and Acellular Therapies Based on Extracellular Vesicles. Cells, 10. 3. Updates on stem cells and their applications in regenerative medicine;Bajada;J. Tissue Eng. Regen. Med.,2008 4. Introduction to stem cells and regenerative medicine;Kolios;Respiration,2013 5. Stem cells in regenerative medicine: Introduction;Ilic;Br. Med. Bull.,2011
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|